Oragenics Files 8-K on Shareholder Nominations

Ticker: OGEN · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1174940

Oragenics INC 8-K Filing Summary
FieldDetail
CompanyOragenics INC (OGEN)
Form Type8-K
Filed DateApr 16, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: governance, shareholder-activism, proxy-contest

Related Tickers: OGEN

TL;DR

Oragenics filed an 8-K about shareholder nominations - looks like a proxy fight might be brewing.

AI Summary

On April 15, 2024, Oragenics, Inc. filed an 8-K report to disclose information regarding shareholder nominations. The filing pertains to Rule 14a-11 of the Exchange Act, which governs proxy solicitations for contested solicitations. This indicates potential upcoming shareholder activism or a contested election for the board of directors.

Why It Matters

This filing signals potential shareholder activism or a contested board election, which could lead to changes in company leadership or strategy.

Risk Assessment

Risk Level: medium — Filings related to shareholder nominations and potential proxy contests often indicate underlying governance disputes or strategic disagreements, which can introduce uncertainty and risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Oragenics, Inc.?

The primary purpose of this 8-K filing is to report on shareholder nominations pursuant to Exchange Act Rule 14a-11, which relates to proxy solicitations for contested solicitations.

What is Exchange Act Rule 14a-11?

Exchange Act Rule 14a-11 pertains to proxy solicitations, specifically addressing requirements for contested solicitations.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is April 15, 2024.

What is Oragenics, Inc.'s principal executive office address?

Oragenics, Inc.'s principal executive office is located at 1990 Main Street, Suite 750, Sarasota, FL 34236.

What is Oragenics, Inc.'s telephone number?

Oragenics, Inc.'s telephone number is 813-286-7900.

Filing Stats: 592 words · 2 min read · ~2 pages · Grade level 14.3 · Accepted 2024-04-15 20:01:16

Filing Documents

SIGNATURES

SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 15 th day of April, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing